SCHEMBL10189720

SCHEMBL10189720

COc1ccc(-c2[nH]nnc2-c2cc(C)c(C)c(OC)c2)cc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 4/20 0.44
TUBB4A P04350 3/20 0.44
TUBB P07437 3/20 0.44
TUBA3C P0DPH7 3/20 0.44
TUBA1B P68363 3/20 0.44
TUBA4A P68366 3/20 0.44
TUBB4B P68371 3/20 0.44
TUBB3 Q13509 3/20 0.44
TUBB2A Q13885 3/20 0.44
TUBB8 Q3ZCM7 3/20 0.44
TUBA3E Q6PEY2 3/20 0.44
TUBA1A Q71U36 3/20 0.44
TUBA1C Q9BQE3 3/20 0.44
TUBB6 Q9BUF5 3/20 0.44
TUBB2B Q9BVA1 3/20 0.44
KDR P35968 2/20 0.41
PIK3CD O00329 1/20 0.41
ABL1 P00519 1/20 0.41
EGFR P00533 1/20 0.41
HCK P08631 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10189700 0.86 ALDH1A1 (0.40) TUBB1ALDH1A1KDM4EMAPTMAPK1
SCHEMBL410489 0.86 TUBB4A (0.58) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL10189739 0.85 CCNB2 (0.36) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL10189742 0.85 CCNB2 (0.38) ALDH1A1MEN1KMT2ALMNAPOLB
SCHEMBL10189745 0.84 PDE4A (0.36) SRCGAAALDH1A1MAPTMEN1
SCHEMBL10189728 0.84 SMPD3 (0.41) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL10189699 0.84 ALDH1A1 (0.35) IDO1ALDH1A1KDM4E
SCHEMBL10189702 0.82 CHEK1 (0.38) ALDH1A1KDM4EHSD17B10MEN1KMT2A
SCHEMBL10189703 0.82 SMPD3 (0.41) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL10189743 0.82 LMNA (0.47) ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 TUBB1 4/4885TUBB4A 18/4885TUBB 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.